March 20, 2025 12:40 PM EDT

Ascendis’ China joint venture, Visen Pharmaceuticals, prices $86M Hong Kong IPO

Kyle LaHucik

Senior Reporter

Visen Pharmaceuticals, a biotech developing much of Ascendis Pharma’s endocrine-related disease pipeline for the China market, will go public on the Hong Kong Stock Exchange …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ascendis’ China joint venture, Visen Pharmaceuticals, prices $86M Hong Kong IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Novo Nordisk says new early R&D structure will ‘future-proof’ its business

Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio

CDC vaccine meeting, delayed earlier this year, is rescheduled

Illumina was built on DNA. Its future could be biology’s next big wave

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'

Two-thirds of recent rare disease drugs relied on just one trial, plus confirmatory evidence, FDA team finds

As­cendis’ Chi­na joint ven­ture, Visen Phar­ma­ceu­ti­cals, prices $86M Hong Kong IPO

Senior Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Ascendis’ China joint venture, Visen Pharmaceuticals, prices $86M Hong Kong IPO